DAVID DARR: Open Payments
NPI 1447293402 · WARSAW, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,346 in 81 payments from 24 companies in 2025. Trend: 2023 $1,299 · 2024 $2,022 · 2025 $1,346
Food & beverage: $1,346
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $264 |
| Vanda Pharmaceuticals Inc. | 3 | $91 |
| Lilly USA, LLC | 5 | $91 |
| PFIZER INC. | 5 | $84 |
| Novo Nordisk Inc | 4 | $77 |
| AstraZeneca Pharmaceuticals LP | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Axsome Therapeutics, Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $60 |
Products named: VRAYLAR, REXULTI, JARDIANCE, FANAPT, UBRELVY, CAPLYTA, AIRSUPRA, Kerendia.
Industry payments across IN — which companies pay providers there.
